Last Wave Technology Competitors

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.